13. SUBSEQUENT EVENTS	12 Months Ended
Dec. 31, 2017
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	In accordance with applicable accounting standards for the disclosure of events that occur after the balance sheet date but before the financial statements are issued, all significant events or transactions that occurred after December 31, 2017, are outlined below: On March 6, 2018 the Company issued 22,651,356 shares of common stock for the conversion of $1,200,000 in convertible debt. In February and March 2018, the company issued 100,567,691 shares of common stock for conversion of 85,561 shares of Series C Convertible Preferred Stock and $1,050,468 of related Series C dividends. As of the date of this report there are no Series C Convertible Preferred stock shares outstanding. In response to the expiration of Applied Nutritionals’ patent covering the use of hydrolyzed collagen in wound care on February 27, 2018, the Company submitted an FDA 510(k) application on March 26, 2018, seeking U.S. marketing clearance for our new internally sourced hydrolyzed collagen.

13. SUBSEQUENT EVENTS

12 Months Ended

Dec. 31, 2017

In accordance with applicable accounting standards for the disclosure of events that occur after the balance sheet date but before the financial statements are issued, all significant events or transactions that occurred after December 31, 2017, are outlined below:

On March 6, 2018 the Company issued 22,651,356 shares of common stock for the conversion of $1,200,000 in convertible debt.

In February and March 2018, the company issued 100,567,691 shares of common stock for conversion of 85,561 shares of Series C Convertible Preferred Stock and $1,050,468 of related Series C dividends.

As of the date of this report there are no Series C Convertible Preferred stock shares outstanding.

In response to the expiration of Applied Nutritionals’ patent covering the use of hydrolyzed collagen in wound care on February 27, 2018, the Company submitted an FDA 510(k) application on March 26, 2018, seeking U.S. marketing clearance for our new internally sourced hydrolyzed collagen.